For research use only. Not for therapeutic Use.
MAHMA NONOate is a NO donor. MAHMA NONOate effectively inhibits platelet aggregation induced by either collagen or ADP[1].
MAHMA NONOate (0.1 nM-100 μM) dose-dependently inhibits platelet aggregation induced by either collagen or ADP[1].
MAHMA NONOate shows inhibitory effects to pulmonary artery and platelet aggregation with log IC50 values of 7.18 and 6.16, respectively[1].
MAHMA NONOate (0.3-10 nmol/kg/min; i.v. once) shows both platelet inhibitory and vasodepressor effects in vivo[2].
| Catalog Number | M091133 |
| CAS Number | 146724-86-9 |
| Synonyms | (Z)-hydroxyimino-[methyl-[6-(methylamino)hexyl]amino]-oxidoazanium |
| Molecular Formula | C8H20N4O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C8H20N4O2/c1-9-7-5-3-4-6-8-11(2)12(14)10-13/h9,13H,3-8H2,1-2H3/b12-10- |
| InChIKey | KQHAZGURWZYZJG-BENRWUELSA-N |
| SMILES | CNCCCCCCN(C)[N+](=NO)[O-] |
| Reference | [1]. Homer KL, Wanstall JC. Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate. Br J Pharmacol. 2002 Dec;137(7):1071-81. [2]. Homer KL, Wanstall JC. Platelet inhibitory effects of the nitric oxide donor drug MAHMA NONOate in vivo in rats. Eur J Pharmacol. 2003 Dec 15;482(1-3):265-70. |
